Publications by authors named "R Bassett"
Objective: To assess the accuracy of CT spectral HU curve assessment of hypodense liver lesions.
Methods: In this retrospective HIPAA-compliant study (January 2016 through May 2023), patients with biopsy-proven pancreatic adenocarcinoma and a biopsied indeterminate liver lesion underwent a DECT abdominal CT scan. Spectral HU curves were provided for each hypodense liver lesion, and slopes were calculated.
Context: The natural history and malignant potential of cases classified as atypical adrenal masses (AAMs) are unknown.
Objective: To describe the radiological characteristics and clinical outcomes of AAMs.
Design And Participants: A multicenter retrospective study.
Objective: The purpose of this study was to evaluate the utility of US for identifying and characterizing lesions detected on molecular breast imaging (MBI).
Methods: A retrospective single-institution review was performed of patients with MBI studies with subsequent US for abnormal MBI findings between January 1, 2015, and September 30, 2021. Medical records, imaging, and histopathology were reviewed.
Article Synopsis
- The study investigates the effectiveness of the anti-EGFR monoclonal antibody panitumumab combined with carboplatin and paclitaxel for treating chemotherapy-resistant triple-negative breast cancer (TNBC) patients.
- It included 43 patients who had not sufficiently responded to prior doxorubicin and cyclophosphamide treatment, achieving a combined pathological complete response/residual cancer burden class I rate of 30.2%.
- The results indicate that panitumumab shows promise as part of neoadjuvant therapy for TNBC, warranting further evaluation in larger clinical trials.
Background: Triple negative breast cancer (TNBC) is an aggressive subtype with poor prognosis. We aimed to determine whether circulating tumor DNA (ctDNA) and circulating tumor cell (CTC) could predict response and long-term outcomes to neoadjuvant chemotherapy (NAC).
Methods: Patients with TNBC were enrolled between 2017-2021 at The University of Texas MD Anderson Cancer Center (Houston, TX).